核黄素四丁酸酯(Riboflavin Butyrate) - 在研适应症：高胆固醇血症，核黄素缺乏_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Riboflavin 2',3',4',5'-tetrabutyrate、Riboflavin Tetabutyrate、Riboflavin butyrate (JP17)

+ [6]

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

高胆固醇血症核黄素缺乏

非在研适应症-

原研机构

Mitsubishi Tanabe Pharma Corp.

在研机构

Nipro ES Pharma KK

成都利尔药业有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1979-09-28),

高胆固醇血症核黄素缺乏

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C33H44N4O10

InChIKeyMJNIWUJSIGSWKK-BBANNHEPSA-N

CAS号752-56-7

关联

32

项与核黄素四丁酸酯相关的临床试验

NCT05027295

/ Recruiting临床3期

A Randomized Study to Evaluate the Safety and Efficacy of Corneal Collagen Crosslinking Performed With Continuous vs Pulsed UVA Light for Reducing Corneal Curvature in Eyes With Keratoconus and Post-refractive Corneal Ectasia

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies.
Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

开始日期2021-07-30

申办/合作机构-

NCT04905108

/ Recruiting临床3期

Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking Using Two Different Riboflavin Administration Protocols

Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery and improved patient comfort in the early postoperative healing period.

开始日期2021-06-02

申办/合作机构-

NCT04897503

/ Recruiting临床3期

Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking Using Riboflavin/Dextran or Riboflavin/Methylcellulose

This study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.

开始日期2021-04-16

申办/合作机构-

100 项与核黄素四丁酸酯相关的临床结果

登录后查看更多信息

100 项与核黄素四丁酸酯相关的转化医学

登录后查看更多信息

100 项与核黄素四丁酸酯相关的专利（医药）

登录后查看更多信息

234

项与核黄素四丁酸酯相关的文献（医药）

2024-01-01·Current Research in Food Science

Impact of butyric acid modification on the structural and functional properties of rice starch

Article

作者: Liu, Xiaofei ; Wang, Bing ; Zhang, Guang ; Zhang, Na ; Wang, Yan ; Bian, Xin ; Wu, Qiaoyan ; Yang, Yang ; Ma, Chunmin ; Xu, Yue

Rice is a food with a high starch content, comprising over 75% of its composition. However, prolonged and excessive consumption of this cereal may lead to elevated blood glucose levels, which can increase the risk of obesity, type 2 diabetes, and cardiovascular disease. Butyric acid (BA), the primary energy source for colonic epithelial cells, exhibits the highest utilization rate among short-chain fatty acids, underscoring its importance for human health. In this study, rice starch butyrate (RSB) samples were synthesized using the aqueous phase process, with broken rice starch (RS) and butyric anhydride serving as the substrate. RSB samples with different degrees of substitution (DS) were produced by modulating the addition amount of butyric anhydride. The crystal structures, morphology of starch granules, pasting properties, thermal stability, and in vitro digestibilities of the RSB were investigated and compared with those of native rice starch. Fourier transform infrared (FTIR) spectroscopy confirmed the successful incorporation of butyryl into the starch molecules. With the increase in DS, the roughness of the RSB material's surface gradually increased, leading to the deterioration of the smooth structure on certain surfaces, which resulted in the appearance of cracks and collapses. Additionally, the crystallinity diminished from 24.77% to 7.41% with increasing DS. Concurrently, in vitro digestive characterisation revealed that the percentage of resistant starch increased from 24.33% to 47.72%. Thus, this study can provide a theoretical basis for the development of novel products of amyl butyrate.

2022-07-04·British Poultry Science3区 · 农林科学

Effects of encapsulated butyrate and salinomycin on gut leakage and intestinal inflammation in broilers

3区 · 农林科学

Article

作者: Naghizadeh, M. ; Klaver, L. ; Engberg, R. M. ; Dalgaard, T. S.

1. The objectives of this study were to i) compare the effects of a commercial product providing encapsulated butyrate (EB) in combination with salinomycin in diets of broilers with impaired intestinal integrity and ii) to identify easy-to-measure biomarkers to evaluate intestinal integrity and health.2. In total, 672 one-day-old male broilers (Ross 308) were randomly assigned to three experimental groups (eight replicates/group): no dietary supplement (control); EB (500 mg/kg, UltraGuard™-DUO, Devenish, Ireland); salinomycin (69 mg/kg feed, Sacox® 120). Impaired gut integrity was induced by a 10 times overdose of a commercially attenuated live vaccine against coccidiosis (Hipracox®, Hipra) on d 17 combined with a grower feed providing rye (50 g/kg diet).3. Improved intestinal integrity and functionality were reflected by reduced fluorescein isothiocyanate-dextran (FITC-D) plasma levels, reduced bacterial translocation to the liver (on d 21) and increased plasma colouration level on d 21 after dietary supplementation of salinomycin, compared to a non-supplemented control diet. Both EB and salinomycin reduced plasma levels of D-lactate (P < 0.05).4. An anti-inflammatory effect of salinomycin was indicated as the transient increase in circulating monocytes observed in the EB and control group from 20 to 28 d of age was slightly but not significantly reduced, in the salinomycin-fed group. Interestingly, greater expression of tumour necrosis factor α (TNF-α) and mucin 2 (MUC2) genes (P = 0.039 and P = 0.067, respectively) were detected in the group receiving salinomycin.5. These effects may have collectively contributed to the significantly improved performance of broilers supplemented with salinomycin. The results indicated that EB at 500 mg/kg in feed, in contrast to salinomycin, neither supported gut health nor modulated intestinal integrity in broilers.

2021-08-20·Science Advances1区 · 综合性期刊

Magnetic-actuated “capillary container” for versatile three-dimensional fluid interface manipulation

1区 · 综合性期刊

ArticleOA

作者: Guo, Qiuquan ; Zhang, Dongxing ; Zhang, Yiyuan ; Cai, Zheren ; Qin, Feifei ; Ye, Yuqing ; Huang, Zhandong ; Xiao, Junfeng ; Song, Yanlin ; Yang, Jun ; Li, Zheng

A previously unexplored approach enables versatile 3D fluid interface manipulation using magnetic-actuated “capillary container.”

100 项与核黄素四丁酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01913	-	S01XA26	DB14727

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高胆固醇血症	日本	Nipro ES Pharma KK	1979-09-28
核黄素缺乏	日本	Nipro ES Pharma KK	1979-09-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00674661 (CXL, CTgov)	临床3期	角膜扩张	130	UVA Irradiation+riboflavin ophthalmic solution (Corneal Collagen Cross-linking (CXL) Treatment Group)	鏇夢淵製簾顧製襯鬱蓋(襯蓋獵夢鑰廠廠壓網艱) = 選鬱鑰網淵遞鏇廠製選窪網窪積蓋遞顧願鏇鏇 (網積鬱鹹餘積壓鏇鹽築, 醖願窪膚築憲壓範餘鹹 ~ 範鑰餘積鹹蓋醖繭糧齋) 更多	-	2017-01-27
				riboflavin ophthalmic solution (Control Group)	鏇夢淵製簾顧製襯鬱蓋(襯蓋獵夢鑰廠廠壓網艱) = 齋餘積鹽醖夢選憲鑰糧窪網窪積蓋遞顧願鏇鏇 (網積鬱鹹餘積壓鏇鹽築, 憲製鏇艱顧淵鏇餘觸繭 ~ 顧選廠顧壓積範繭壓顧) 更多
NCT00647699 (CXL, CTgov)	临床3期	圆锥角膜	147	UVA Irradiation+riboflavin ophthalmic solution (Corneal Collagen Cross-linking (CXL) Treatment Group)	築網窪積膚積築積鬱構(衊襯襯窪襯醖衊齋鏇選) = 廠醖選築觸鹽鬱鑰鑰網繭餘鹽艱簾窪夢鹽糧鬱 (製選憲鹹顧糧膚衊選鏇, 廠鏇廠夢構襯鹹鹽糧顧 ~ 鹽繭醖鑰鹽憲鹽獵夢憲) 更多	-	2016-07-07
				riboflavin ophthalmic solution (Control Group)	築網窪積膚積築積鬱構(衊襯襯窪襯醖衊齋鏇選) = 積襯鑰鹽蓋壓鏇窪憲鏇繭餘鹽艱簾窪夢鹽糧鬱 (製選憲鹹顧糧膚衊選鏇, 簾簾廠構築蓋蓋願蓋鹽 ~ 醖繭衊醖選餘網鏇憲蓋) 更多
NCT01190306 (CTgov)	临床3期	圆锥角膜	127	The VEGA UV-A Illumination System+Riboflavin (CXL Treatment)	淵範壓繭壓壓鹹艱蓋積(壓齋製獵獵鏇顧衊餘衊) = 鹹選製觸鏇鹽艱鹹繭遞積積簾築積鏇獵餘糧憲 (蓋窪遞獵顧鑰鬱壓繭鬱, 獵鏇鹽遞鹽範遞齋齋鑰 ~ 蓋廠糧襯網觸艱憲衊顧) 更多	-	2013-03-04
				Riboflavin (Sham Control)	淵範壓繭壓壓鹹艱蓋積(壓齋製獵獵鏇顧衊餘衊) = 廠鬱鑰壓憲顧構齋觸鑰積積簾築積鏇獵餘糧憲 (蓋窪遞獵顧鑰鬱壓繭鬱, 憲廠觸網製襯窪廠構積 ~ 網獵蓋選襯壓艱觸獵觸) 更多
NCT01398839 (CTgov)	临床3期	-	103	VEGA UV-A Illumination System+Riboflavin (CXL Treatment)	醖壓鏇構簾簾築構網選(餘顧鏇網鹽壓選遞製醖) = 獵獵齋鏇齋夢鹽鬱製簾積積顧鏇鹽獵壓膚觸壓 (鬱醖淵鹽壓鑰糧醖構齋, 顧糧範積廠顧襯壓鹽窪 ~ 壓衊鹽構鏇積壓範窪衊) 更多	-	2013-03-04
				Riboflavin (Sham Control)	醖壓鏇構簾簾築構網選(餘顧鏇網鹽壓選遞製醖) = 糧鏇觸鹹鬱蓋衊顧憲繭積積顧鏇鹽獵壓膚觸壓 (鬱醖淵鹽壓鑰糧醖構齋, 遞遞窪廠鏇艱獵糧襯廠 ~ 範膚衊餘艱簾憲窪壓糧) 更多